DNA Technology: MonogenScreen (Genetic Disease Test)

2023: Test Development

The metropolitan company "DNA-Technology" has developed three types of tests to assess the risk of giving birth to a child with hereditary diseases. This was announced on January 27, 2023 by the head of the Department of Investment and Industrial Policy of Moscow, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky.

Over 200 metropolitan enterprises as of January 2023 are engaged in the production of drugs and medical devices. They offer both standard and innovative drugs and solutions for the treatment and diagnosis of various diseases. Thus, the metropolitan company "DNA-Technology" has developed three types of tests that allow you to determine hereditary genetic diseases in a child at the stage of planning and early pregnancy, as well as in newborns. Tests have already been put into production, the planned volume of production is over 20 thousand units of products annually. Tests will be delivered to pharmacies and medical institutions throughout the country, - said Vladislav Ovchinsky.

DNA-Technology is one of the manufacturers of equipment and reagents for PCR laboratories. For 30 years, the company has been developing and implementing technological solutions in the field of molecular genetic diagnostics, among them - affordable technologies in the field of reproductive genetics: for safe prenatal and neonatal screening, pregnancy planning, preimplantation genetic testing.

One of the developments is the MonogenScreen test, which allows detecting mutations in genes responsible for monogenic diseases at the pregnancy planning stage. The study is performed by PCR and can be used for mass screening using automation. Equipment and reagents providing a full process cycle are also developed and manufactured by DNA-Technology. Another product is the AneuScreen ILM test, thanks to which in the first months of pregnancy it is possible to assess the risks of aneuploidia and chromosomal abnormalities in the fetus. It is a non-invasive method of prenatal screening for aneuploidias, based on analysis of fetal extracellular DNA in the mother's blood.

The reagent kit "NeoScreen SMA/TREC/KREC" allows you to identify the most common genetic diseases in newborns that pose a threat to the life and health of the child. This kit is designed to screen newborns for spinal muscular atrophy and primary immunodeficiency. The study is carried out using dry spots of capillary blood plotted on neonatal screening maps by real-time PCR and meets all the requirements necessary for inclusion in the neonatal screening program.

{{quote 'All studies fully comply with Russian and international quality standards. PCR and NGS diagnostic methods will make it possible to qualitatively transform the prevention of genetic diseases in newborns. For January 2023, we are working on a test that will allow assessing the intestinal microbiota in children, and we hope to launch the development on the market in the near future, "said Vladimir Kolin, General Director of DNA-Technology LLC. }}

See also

• Pregnancy and childbirth
• Genetics